How Much Does Wegovy & Ozempic Cost in 2026? Full Price Breakdown

01

Why Ozempic and Wegovy cost so much (and why the sticker price is misleading)

Ozempic and Wegovy are both semaglutide, made by Novo Nordisk.

Ozempic is FDA-approved for type 2 diabetes; Wegovy is approved for chronic weight management (and, more recently, to reduce cardiovascular risk in certain adults).

Same molecule, different label — and that difference drives how insurance treats them.

The "list price" (also called WAC, wholesale acquisition cost) is the headline number you see in the news. It's the manufacturer's benchmark price before any rebates, insurance, or coupons.

Real-world spending is almost always lower because of three levers:

1. 1

   Insurance

   if your plan covers the drug for your diagnosis.

2. 2

   Manufacturer savings cards

   copay assistance for commercially insured patients.

3. 3

   Cash-pay direct pharmacy

   Novo Nordisk's NovoCare program sells directly to self-pay patients well below list price.

Understanding these three levers is the whole game. Let's break down each drug.

02

How much does Ozempic cost?

Ozempic list price (without insurance)

The list price of Ozempic is around $970–$1,000 per month for a standard once-weekly pen.

At retail pharmacies, cash prices without any discount often land in the $1,000–$1,200+ range per month, according to GoodRx and drug-pricing databases.

Ozempic cash-pay price (NovoCare / self-pay)

Most self-pay patients do not pay retail. Through Novo Nordisk's self-pay channel in 2026:

• $199/month for the first two months (0.25 mg and 0.5 mg starter doses) as a limited-time new-patient offer.
• $349/month thereafter for the 0.25 mg, 0.5 mg, or 1 mg pens.
• $499/month for the 2 mg dose.

Ozempic with insurance + savings card

If you have commercial (private) insurance that covers Ozempic for type 2 diabetes, the Ozempic Savings Card can bring your copay down to as little as $25 per month for eligible patients (typically with a monthly cap and a maximum annual savings).

To qualify you generally need commercial insurance, a valid prescription, and U.S. residency.

Important: If you're enrolled in Medicare, Medicaid, TRICARE, VA, or any government program, you are not eligible for the manufacturer savings card. Medicare Part D does cover Ozempic for diabetes (subject to Inflation Reduction Act price negotiation for 2026), so many Medicare enrollees with T2D pay roughly $50/month or less under the redesigned Part D benefit — but Medicare does not cover Ozempic for weight loss.

The Ozempic pill

Novo Nordisk now also offers an oral semaglutide option.

Self-pay pricing runs about $149/month (1.5 mg), $199/month (4 mg), and $299/month (9 mg), depending on dose and current promotions.

03

How much does Wegovy cost?

Wegovy list price (without insurance)

Wegovy's list price is about $1,350 per month — for both the weekly injection pen and the newer oral pill formulation.

Wegovy cost without insurance (cash-pay / NovoCare Pharmacy)

This is where the number that scares people gets a lot friendlier. Through NovoCare Pharmacy self-pay in 2026:

• $199/month for each of the first two months (0.25 mg and 0.5 mg), for new patients — a promotion running through the end of 2026.
• $349/month thereafter for the 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg maintenance doses.
• $399/month for the higher-dose Wegovy HD 7.2 mg.
• Wegovy pill: roughly $149–$299/month depending on dose.

Wegovy insurance coverage + savings card

Wegovy is approved for weight management, and coverage is more variable than for diabetes drugs — many commercial plans exclude "weight-loss drugs," while others cover them with prior authorization.

• If your commercial plan covers Wegovy, the Wegovy Savings Offer can reduce your copay to as low as $0 for many eligible patients (with a monthly savings cap).
• If your commercial plan does not cover Wegovy, the savings card historically offers a reduced self-pay-style rate — but the more reliable route today is the flat NovoCare cash price above.
• To use the savings offer you generally must be 18+, have commercial insurance, and a valid prescription. Government-insured patients are excluded.

Medicare and Wegovy in 2026

A notable 2026 development: starting July 1, 2026, a Medicare "GLP-1 bridge" began covering Wegovy (and Zepbound KwikPen) for weight management at around a $50 copay for eligible beneficiaries.

This is new and evolving — confirm eligibility with your Part D plan, as details and the list of covered products may change.

04

Ozempic & Wegovy price comparison table (2026)

Prices as of mid-2026 — verify current pricing at ozempic.com, novocare.com, and GoodRx. Actual cost depends on dose, pharmacy, plan, and promotions.

05

How to lower your GLP-1 cost: a step-by-step playbook

1. Confirm your diagnosis and the right drug

Insurance follows the label. If you have type 2 diabetes, Ozempic (or Mounjaro) is far more likely to be covered.

If you're treating obesity/overweight, Wegovy (or Zepbound) is the on-label choice — but weight-loss coverage is spottier.

Ask your prescriber which drug matches both your medical need and your plan's formulary.

2. Check your formulary before you fill

Log into your insurer's member portal or call the number on your card and ask: *Is this drug on formulary? What tier? Is prior authorization required?

What's my copay?* Five minutes here can save you hundreds.

3. Get prior authorization right the first time

Denials are often about paperwork, not eligibility. Prior authorization typically requires documentation such as your A1C (for diabetes), BMI and weight history, prior diet/exercise attempts, and related conditions (hypertension, sleep apnea, high cholesterol).

Ask your clinic to submit a complete PA packet up front, and appeal denials — appeals frequently succeed.

4. Stack the manufacturer savings card (if commercially insured)

If you have private insurance and the drug is covered, enroll in the Ozempic Savings Card or Wegovy Savings Offer before you fill.

This is the single biggest lever for insured patients — potentially $0–$25/month.

5. If uninsured or excluded, use the cash-pay direct channel

The NovoCare / self-pay flat prices ($199 intro → $349+/mo) are usually far cheaper than walking up to a pharmacy counter. Enroll online, or ask your pharmacy about the self-pay program.

6. Compare GoodRx and pharmacy coupons

For some doses and pharmacies, a GoodRx or similar discount coupon beats the cash price.

It costs nothing to compare — check GoodRx, your pharmacy's own discount program, and the manufacturer price, then pick the lowest.

7. Consider telehealth

Telehealth platforms bundle a prescriber visit (often $0–$49) with prescription and delivery.

They can streamline PA paperwork and self-pay ordering — just make sure you're getting FDA-approved, brand-name medication from a licensed pharmacy, not an unregulated product.

06

Cheaper alternatives compared

Tirzepatide: Mounjaro & Zepbound (Eli Lilly)

Tirzepatide is a dual-action GLP-1/GIP drug often producing greater average weight loss than semaglutide.

Like semaglutide, it has a diabetes label (Mounjaro) and a weight label (Zepbound).

A word on compounded semaglutide

Compounded GLP-1s were widely (and cheaply) available during the 2023–2024 shortage.

That door has largely closed: after the FDA removed semaglutide and tirzepatide from the shortage list, large-scale compounding was wound down, and in 2026 the FDA proposed permanently removing these molecules from the 503B outsourcing bulks list.

Some individualized 503A/503B compounding may continue under strict conditions, but mass-produced compounded semaglutide is no longer generally permitted. Be cautious of online sellers advertising cheap "semaglutide" — verify legitimacy and prioritize FDA-approved products.

Older / oral options

• Rybelsus — Novo Nordisk's oral semaglutide for diabetes, sometimes a lower-cost entry point.
• Older weight-loss meds (phentermine, etc.) are far cheaper but work differently and aren't GLP-1s.

The honest takeaway: for cash-pay weight management, Zepbound via LillyDirect and Wegovy via NovoCare are currently the two most competitive brand-name routes.

For diabetes with commercial insurance, a covered Ozempic or Mounjaro with a savings card is usually cheapest.

07

The cost of *stopping* — a hidden line item

GLP-1s are generally long-term therapies. Studies show much of the lost weight tends to return after stopping, so the realistic budget is ongoing, not a one-time course.

That makes the sustainable monthly price — not the promotional first-month price — the number that matters.

Factor in a maintenance strategy: nutrition, movement, sleep, and behavior change that you can keep up whether or not you stay on medication.

This is exactly where a habit and wellness routine (the kind Havit is built around) protects your investment.

08

Why HAVIT — Medication + Behavior Change, in One App

GLP-1 medications can meaningfully reduce weight — but the number on the scale is only part of the story.

Roughly 20–40% of the weight lost on GLP-1 therapy can come from lean (muscle) tissue rather than fat (Neeland et al., Diabetes, Obesity and Metabolism, 2024), and results tend to fade once the medication stops unless new habits take their place.

That's why leading guidance treats medication as one part of care, not the whole: the U.S. Preventive Services Task Force recommends that adults with obesity be offered intensive, multicomponent behavioral interventions (USPSTF, Grade B).

HAVIT is built for exactly this moment — one app that unites medication tracking, body composition, nutrition and protein, daily habit-building, and an AI coach that adapts to you.

Across our own 1,090 GLP-1 users, the most consistent trackers built the strongest habits (see the GLP-1 habit report).

Manage the medicine and the muscle — together. Start with HAVIT →

Ozempic & Wegovy price comparison table (2026)

Related articles